The database of proteins secreted into blood provides a resource for basic research as well as a potential list of targets for drug and diagnostics development.
With the purchase, Canopy acquires Core's CLIA facility from which it will provide its multi-omic immune profiling services.
The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.
The Human Protein Atlas was founded in 2003 to map all the human proteins in cells, tissues, and organs using a variety of omics technologies.
The researchers used the SomaScan platform to measure 5,000 plasma proteins across 17,000 patients and develop protein profiles correlated to 11 health conditions.
Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's oncology database.
The partners are developing a new lab that will focus on research into protein biomarkers with medical, agricultural, and environmental applications.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
The firm will use the net proceeds to repurchase up to about $50 million of its senior convertible note due 2034, as well as for general corporate purposes.
The deal includes Expedeon's core proteomics business, as well as its immunology-focused subsidiaries Innova Biosciences and TGR Biosciences.
UK-based Abcam has also taken an undisclosed equity stake in BrickBio, located in Boston, and will work with the company to further develop its platform.
The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.
The collaborators are developing a sample prep solution for the Mission Bio Tapestri platform and are working on a hematology-focused panel.
The researchers suggested that the system's combination of speed and high coverage could enable new applications within the imaging mass spec space.
Fluidigm logged $26.4 million in revenues compared to $29.0 million a year ago and well short of analysts' consensus estimate of $28.7 million.
Among the study's goals is to identify molecular signatures that can distinguish idiopathic pulmonary fibrosis from interstitial lung disease.
The researchers combined genomic, transcriptomic, and proteomic profiling to gain insight into the basic biology and possible treatments for the disease.
Revenues rose to $521.1 million from $466.6 million in Q3 2018, beating the consensus Wall Street estimate of $496.7 million.
Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.
In a study published this week, researchers presented a Simoa-based assay for tuberculosis that could ultimately be packaged as a point-of-care test.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.